<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Assembly Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/assembly-biosciences-inc</link>
<description>Latest news and press releases for Assembly Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/assembly-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683548c178dffbe2df0e3f58.webp</url>
<title>Assembly Biosciences Inc</title>
<link>https://6ix.com/company/assembly-biosciences-inc</link>
</image>
<item>
<title>Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-highlights-presentations-on-positive-phase-1b-data-for-abi-5366-and-abi-1179-in-recurrent-genital-herpes-at-escmid-global-2026</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-highlights-presentations-on-positive-phase-1b-data-for-abi-5366-and-abi-1179-in-recurrent-genital-herpes-at-escmid-global-2026</guid>
<pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
<description>– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for ABI-5366 and ABI-1179, herpes simplex virus (HSV) helicase-</description>
</item>
<item>
<title>Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-year-end-2025-financial-results-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-year-end-2025-financial-results-and-recent-highlights</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following</description>
</item>
<item>
<title>Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – FOSTER</description>
</item>
<item>
<title>Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-positive-interim-210500095</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-positive-interim-210500095</guid>
<pubDate>Mon, 08 Dec 2025 21:05:00 GMT</pubDate>
<description>– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 – – Company to hold conference call today</description>
</item>
<item>
<title>Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate i...</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-positive-interim-results-from-phase-1b-clinical-studies-of-long-acting-helicase-primase-inhibitor-candidates-abi-1179-and-abi-5366-showing-reductions-in-viral-shedding-rate-and-virologically-confirmed-genital-lesion-rate-i</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-positive-interim-results-from-phase-1b-clinical-studies-of-long-acting-helicase-primase-inhibitor-candidates-abi-1179-and-abi-5366-showing-reductions-in-viral-shedding-rate-and-virologically-confirmed-genital-lesion-rate-i</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and</description>
</item>
<item>
<title>Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-third-quarter-210500786</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-third-quarter-210500786</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – Announced Phase 1a interim results for orally bioavailable HDV entry inhibitor candidate ABI-6250 supporting progression into Phase 2 evaluation – – Additional interim Phase 1b data readouts from HSV program anticipated to include monthly oral dosing for ABI-5366 and two cohorts of</description>
</item>
<item>
<title>Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-presents-positive-phase-130000316</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-presents-positive-phase-130000316</guid>
<pubDate>Fri, 07 Nov 2025 13:00:00 GMT</pubDate>
<description>– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for its next-generation investigational capsid assembly modulator (CAM) ABI-4334 featured in a</description>
</item>
<item>
<title>Assembly Biosciences Announces Upcoming Investor Conference Participation</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-announces-upcoming-investor-110000244</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-announces-upcoming-investor-110000244</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will participate in fireside chats at two upcoming investor conferences. H.C. Wainwright Liver Disease Virtual ConferenceAnuj Gaggar, MD, PhD, chief medical officer, will present in a pre-recorded fireside chat that will be available on demand during the H.C. Wainwrig</description>
</item>
<item>
<title>Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-presents-interim-phase-120000776</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-presents-interim-phase-120000776</guid>
<pubDate>Fri, 10 Oct 2025 12:00:00 GMT</pubDate>
<description>– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in HSV-2 shedding rate, high viral load shedding rate and genital lesion rate observed in the cohort evaluating 350 mg weekly oral dose compared to placebo – – Interim data evaluating a monthly dosing regimen of ABI-5366 and weekly dosing for second HSV helicase-primase inhibitor candidate ABI-1179 exp</description>
</item>
<item>
<title>Assembly Biosciences Announces Pricing of $175 Million in Equity Financings</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-announces-pricing-175-120500215</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-announces-pricing-175-120500215</guid>
<pubDate>Fri, 08 Aug 2025 12:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up</description>
</item>
<item>
<title>Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-positive-interim-120000580</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-positive-interim-120000580</guid>
<pubDate>Fri, 08 Aug 2025 12:00:00 GMT</pubDate>
<description>– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to placebo over same period – – Favorable safety and tolerability profile observed in the first two cohorts evaluating weekly oral doses of ABI-5366 – S</description>
</item>
<item>
<title>Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-interim-phase-200500710</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-interim-phase-200500710</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further pharmacological assessment to be conducted in parallel with Phase 2 preparation – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics</description>
</item>
<item>
<title>Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-second-quarter-200500409</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-second-quarter-200500409</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 – – Positive topline data reported for Phase 1b study of ABI-4334, a next-generation highly potent capsid assembly modulator candidate, in participants with chronic hepatitis B virus (HBV) – – Interim data, including a biomarker for target engagement, reported from Phase 1a study</description>
</item>
<item>
<title>Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-presents-data-highlighting-070000047</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-presents-data-highlighting-070000047</guid>
<pubDate>Sat, 26 Jul 2025 07:00:00 GMT</pubDate>
<description>– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates – – Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted – – Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – SOUTH SAN FRANCISCO, Calif., July 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB</description>
</item>
<item>
<title>Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-doses-first-participant-120000800</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-doses-first-participant-120000800</guid>
<pubDate>Mon, 30 Jun 2025 12:00:00 GMT</pubDate>
<description>– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI-1179 and ABI-5366 running concurrently with interim data for both candidates on track for fall 2025 – SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting seriou</description>
</item>
<item>
<title>Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-positive-topline-120000228</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-positive-topline-120000228</guid>
<pubDate>Wed, 25 Jun 2025 12:00:00 GMT</pubDate>
<description>– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort consistent with findings in 150 mg cohort, supporting ability of 150 mg dose to achieve saturated inhibition of viral replication, as anticipated – – Trial completion triggers opt-in point under collaboration with Gilead Sciences, Inc. following d</description>
</item>
<item>
<title>Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-present-during-jefferies-200500356</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-present-during-jefferies-200500356</guid>
<pubDate>Tue, 27 May 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events a</description>
</item>
<item>
<title>Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-first-quarter-200500704</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-reports-first-quarter-200500704</guid>
<pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
<description>– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted at ICAR, ESCMID and EASL 2025 – SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported</description>
</item>
<item>
<title>New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/preclinical-data-assembly-biosciences-oral-120000607</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/preclinical-data-assembly-biosciences-oral-120000607</guid>
<pubDate>Wed, 07 May 2025 12:00:00 GMT</pubDate>
<description>– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data anticipated in the first half of 2025 – SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announc</description>
</item>
<item>
<title>Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress</title>
<link>https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-presents-data-highlighting-060000870</link>
<guid isPermaLink="true">https://6ix.com/company/assembly-biosciences-inc/news/assembly-biosciences-presents-data-highlighting-060000870</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 GMT</pubDate>
<description>– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional poster presentation highlights new insights in genital herpes prevalence and treatment patterns in the U.S. – – ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWI</description>
</item>
</channel>
</rss>